Do not stop or change your medication without speaking to a pharmacist or healthcare professional.

Recalls / IMBRUVICA (ibrutinib), 140 mg, 280 mg, 420 mg and 560 mg tablets, and 140 mg capsules

IMBRUVICA (ibrutinib) - Risk of Serious and Fatal Cardiac Arrhythmias or Cardiac Failure

Drugs · Last updated 2022-08-29

Why it was recalled

New safety information - Product safety

Source

Other Recent Recalls

Apo-Semaglutide Injection

Apo-Semaglutide Injection : Incorrect dose display

Type II2026-09-24

Moderate health risk

Novo-Gesic Forte 500 mg tablets (acetaminophen)

Generic acetaminophen by Teva recalled because it may contain foreign material

Type I2026-09-10

Highest health risk

JAMP Temozolomide

JAMP Temozolomide: Out-of-Specification (Assay)

Type II2026-08-31

Moderate health risk

Recall data is sourced from Health Canada's Recalls and Safety Alerts open dataset. MedShort.ca is an independent tracking tool and does not provide medical advice — for questions about this recall, contact the manufacturer or your pharmacist, or read the full notice linked above.